Introduction – Company Background

GuangXin Industrial Co., Ltd. is a specialized manufacturer dedicated to the development and production of high-quality insoles.

With a strong foundation in material science and footwear ergonomics, we serve as a trusted partner for global brands seeking reliable insole solutions that combine comfort, functionality, and design.

With years of experience in insole production and OEM/ODM services, GuangXin has successfully supported a wide range of clients across various industries—including sportswear, health & wellness, orthopedic care, and daily footwear.

From initial prototyping to mass production, we provide comprehensive support tailored to each client’s market and application needs.

At GuangXin, we are committed to quality, innovation, and sustainable development. Every insole we produce reflects our dedication to precision craftsmanship, forward-thinking design, and ESG-driven practices.

By integrating eco-friendly materials, clean production processes, and responsible sourcing, we help our partners meet both market demand and environmental goals.

Core Strengths in Insole Manufacturing

At GuangXin Industrial, our core strength lies in our deep expertise and versatility in insole and pillow manufacturing. We specialize in working with a wide range of materials, including PU (polyurethane), natural latex, and advanced graphene composites, to develop insoles and pillows that meet diverse performance, comfort, and health-support needs.

Whether it's cushioning, support, breathability, or antibacterial function, we tailor material selection to the exact requirements of each project-whether for foot wellness or ergonomic sleep products.

We provide end-to-end manufacturing capabilities under one roof—covering every stage from material sourcing and foaming, to precision molding, lamination, cutting, sewing, and strict quality control. This full-process control not only ensures product consistency and durability, but also allows for faster lead times and better customization flexibility.

With our flexible production capacity, we accommodate both small batch custom orders and high-volume mass production with equal efficiency. Whether you're a startup launching your first insole or pillow line, or a global brand scaling up to meet market demand, GuangXin is equipped to deliver reliable OEM/ODM solutions that grow with your business.

Customization & OEM/ODM Flexibility

GuangXin offers exceptional flexibility in customization and OEM/ODM services, empowering our partners to create insole products that truly align with their brand identity and target market. We develop insoles tailored to specific foot shapes, end-user needs, and regional market preferences, ensuring optimal fit and functionality.

Our team supports comprehensive branding solutions, including logo printing, custom packaging, and product integration support for marketing campaigns. Whether you're launching a new product line or upgrading an existing one, we help your vision come to life with attention to detail and consistent brand presentation.

With fast prototyping services and efficient lead times, GuangXin helps reduce your time-to-market and respond quickly to evolving trends or seasonal demands. From concept to final production, we offer agile support that keeps you ahead of the competition.

Quality Assurance & Certifications

Quality is at the heart of everything we do. GuangXin implements a rigorous quality control system at every stage of production—ensuring that each insole meets the highest standards of consistency, comfort, and durability.

We provide a variety of in-house and third-party testing options, including antibacterial performance, odor control, durability testing, and eco-safety verification, to meet the specific needs of our clients and markets.

Our products are fully compliant with international safety and environmental standards, such as REACH, RoHS, and other applicable export regulations. This ensures seamless entry into global markets while supporting your ESG and product safety commitments.

ESG-Oriented Sustainable Production

At GuangXin Industrial, we are committed to integrating ESG (Environmental, Social, and Governance) values into every step of our manufacturing process. We actively pursue eco-conscious practices by utilizing eco-friendly materials and adopting low-carbon production methods to reduce environmental impact.

To support circular economy goals, we offer recycled and upcycled material options, including innovative applications such as recycled glass and repurposed LCD panel glass. These materials are processed using advanced techniques to retain performance while reducing waste—contributing to a more sustainable supply chain.

We also work closely with our partners to support their ESG compliance and sustainability reporting needs, providing documentation, traceability, and material data upon request. Whether you're aiming to meet corporate sustainability targets or align with global green regulations, GuangXin is your trusted manufacturing ally in building a better, greener future.

Let’s Build Your Next Insole Success Together

Looking for a reliable insole manufacturing partner that understands customization, quality, and flexibility? GuangXin Industrial Co., Ltd. specializes in high-performance insole production, offering tailored solutions for brands across the globe. Whether you're launching a new insole collection or expanding your existing product line, we provide OEM/ODM services built around your unique design and performance goals.

From small-batch custom orders to full-scale mass production, our flexible insole manufacturing capabilities adapt to your business needs. With expertise in PU, latex, and graphene insole materials, we turn ideas into functional, comfortable, and market-ready insoles that deliver value.

Contact us today to discuss your next insole project. Let GuangXin help you create custom insoles that stand out, perform better, and reflect your brand’s commitment to comfort, quality, and sustainability.

🔗 Learn more or get in touch:
🌐 Website: https://www.deryou-tw.com/
📧 Email: shela.a9119@msa.hinet.net
📘 Facebook: facebook.com/deryou.tw
📷 Instagram: instagram.com/deryou.tw

Taiwan insole OEM manufacturing factory

Are you looking for a trusted and experienced manufacturing partner that can bring your comfort-focused product ideas to life? GuangXin Industrial Co., Ltd. is your ideal OEM/ODM supplier, specializing in insole production, pillow manufacturing, and advanced graphene product design.

With decades of experience in insole OEM/ODM, we provide full-service manufacturing—from PU and latex to cutting-edge graphene-infused insoles—customized to meet your performance, support, and breathability requirements. Our production process is vertically integrated, covering everything from material sourcing and foaming to molding, cutting, and strict quality control.Indonesia graphene product OEM service

Beyond insoles, GuangXin also offers pillow OEM/ODM services with a focus on ergonomic comfort and functional innovation. Whether you need memory foam, latex, or smart material integration for neck and sleep support, we deliver tailor-made solutions that reflect your brand’s values.

We are especially proud to lead the way in ESG-driven insole development. Through the use of recycled materials—such as repurposed LCD glass—and low-carbon production processes, we help our partners meet sustainability goals without compromising product quality. Our ESG insole solutions are designed not only for comfort but also for compliance with global environmental standards.Smart pillow ODM manufacturer Indonesia

At GuangXin, we don’t just manufacture products—we create long-term value for your brand. Whether you're developing your first product line or scaling up globally, our flexible production capabilities and collaborative approach will help you go further, faster.Graphene sheet OEM supplier Taiwan

📩 Contact us today to learn how our insole OEM, pillow ODM, and graphene product design services can elevate your product offering—while aligning with the sustainability expectations of modern consumers.Vietnam custom insole OEM supplier

Scientists have discovered that the refueling of T cells’ toxic weapons is regulated by mitochondria. This allows T cells to kill and kill again. Credit: University of Cambridge Scientists discover how T cell assassins reload their weapons to kill and kill again. Cambridge researchers have discovered how T cells – an important component of our immune system – are able to keep on killing as they hunt down and kill cancer cells, repeatedly reloading their toxic weapons. Cytotoxic T cells are specialist white blood cells that are trained by our immune system to recognize and eliminate threats – including tumor cells and cells infected with invading viruses, such as SARS-CoV-2, which causes COVID-19. They are also at the heart of new immunotherapies that promise to transform cancer treatment.  Professor Gillian Griffiths from the Cambridge Institute for Medical Research, who led the research, said: “T cells are trained assassins that are sent on their deadly missions by the immune system. There are billions of them in our blood, each engaged in a ferocious and unrelenting battle to keep us healthy. “Once a T cell has found its target, it binds to it and releases its toxic cargo. But what is particularly remarkable is that they are then able to go on to kill and kill again. Only now, thanks to state-of-the-art technologies, have we been able to find out how they reload their weapons.” Today, in a study published in Science, the team have shown that the refueling of T cells’ toxic weapons is regulated by mitochondria. Mitochondria are often referred to as a cell’s batteries as they provide the energy that power their function. However, in this case the mitochondria use an entirely different mechanism to ensure the killer T cells have sufficient ‘ammunition’ to destroy their targets. Professor Griffiths added: “These assassins need to replenish their toxic payload so that they can keep on killing without damaging the T cells themselves. This careful balancing act turns out to be regulated by the mitochondria in T cells, which set the pace of killing according to how quickly they themselves can manufacture proteins. This enables killer T cells to stay healthy and keep on killing under challenging conditions when a prolonged response is required.” To accompany the study, Professor Griffiths and colleagues have released footage showing killer T cells as they hunt down and eliminate cancer cells. One teaspoon full of blood alone is believed to have around 5 million T cells, each measuring around 10 micrometers in length, about a tenth the width of a human hair. The cells, seen in the video as red or green amorphous ‘blobs’, move around rapidly, investigating their environment as they travel. When a T cell finds an infected cell or, in the case of the film, a cancer cell, membrane protrusions rapidly explore the surface of the cell, checking for tell-tale signs that this is an uninvited guest. The T cell binds to the cancer cell and injects poisonous ‘cytotoxin’ proteins down special pathways called microtubules to the interface between the T cell and the cancer cell, before puncturing the surface of the cancer cell and delivering its deadly cargo. Reference: “Mitochondrial translation is required for sustained killing by cytotoxic T cells” by Miriam Lisci, Philippa R. Barton, Lyra O. Randzavola, Claire Y. Ma, Julia M. Marchingo, Doreen A. Cantrell, Vincent Paupe, Julien Prudent, Jane C. Stinchcombe and Gillian M. Griffiths, 15 October 2021, Science. DOI: 10.1126/science.abe9977 The research was funded by Wellcome.

Researchers at the University of Basel have developed a method to simultaneously test the effects of over 1,500 active substances on cell metabolism. This innovative approach has revealed previously unknown mechanisms of action for existing medications. Credit: SciTechDaily.com Scientists have unveiled a groundbreaking method to test how thousands of active substances influence cellular metabolism simultaneously. By using high-throughput metabolomics and mass spectrometry, they identified unexpected effects of existing medications, paving the way for repurposing drugs and accelerating drug discovery. This approach could one day align patient-specific metabolic data with tailored treatments. Understanding Active Substances and Cell Metabolism How do active substances affect metabolic processes in cells? Answering this question could unlock valuable insights for developing new medications. However, investigating how a library of compounds interacts with cellular metabolism has historically been a resource-intensive task. Now, researchers from the Department of Biomedicine at the University of Basel have introduced a groundbreaking method for testing the metabolic effects of thousands of substances simultaneously. Their findings, based on a technique called high-throughput metabolomics, were published today (January 28) in the journal Nature Biotechnology. Predicting Side Effects and Drug Interactions “When we have a better understanding of exactly how active substances intervene in cell metabolism, the development of medication can be accelerated,” explains Professor Mattia Zampieri. “Our method provides additional characterization of the substances, from which we can infer possible side effects or interactions with other medications.” The researchers, led by Dr. Laurentz Schuhknecht, lead author of the study, grew cells in thousands of little wells in cell culture plates. They then treated the cells in each well with one of over 1500 substances from a compound library, and used a method called mass spectrometry to measure how thousands of small biomolecules inside the cells (known as metabolites) change upon treatment. This allowed the research team to gather data on the changes of over 2000 metabolic products in the cells for each active compound. They then compared these changes with those obtained from untreated cells via computer-aided analysis. This resulted in an overview of the effects on cell metabolism of each active substance, which gave them a very accurate picture of its respective mode of action. Surprising Discoveries in Drug Mechanisms “Commercially available drugs can influence cell metabolism much more than we had imagined,” says Zampieri, summing up the results of the experiments. Particularly of note were the previously unknown modes of action of common medications. For example, the team discovered that tiratricol, a drug for treating a rare condition involving the thyroid gland function, aside its primary mode of action also influences the production of certain nucleotides, the building blocks for DNA synthesis. “This medication would therefore potentially be a good candidate for a new field of application: modulating nucleotide biosynthesis and hence being used for instance in cancer therapy to inhibit tumor growth,” says Schuhknecht. Leveraging Data for AI-Driven Drug Design Comprehensive data from high-throughput methods such as this, can help train artificial intelligence for designing new medications. “Our long-term vision is to match patient-specific metabolic profiles of a disease with the mode of metabolic interference of thousands of compound candidates to unravel the best medication able to revert the molecular changes induced by the disease,” says Zampieri. In order to get closer to this vision, it is not only important to understand the action of the substances on metabolism, the pharmacologist emphasizes. It is equally important how the human body processes the active substances and thus how it changes their effect. The scientists are therefore conducting further research to examine the interaction between the body and active substances more closely. Reference: “A human metabolic map of pharmacological perturbations reveals drug modes of action” by Laurentz Schuhknecht, Karin Ortmayr, Jürgen Jänes, Martina Bläsi, Eleni Panoussis, Sebastian Bors, Terézia Dorčáková, Tobias Fuhrer, Pedro Beltrao and Mattia Zampieri, 28 January 2025, Nature Biotechnology. DOI: 10.1038/s41587-024-02524-5

A recent Scripps Research study has identified the detailed structures of PLD3 and PLD4, enzymes critical for nucleic acid degradation and immune regulation. The discovery, enabling the understanding of diseases like lupus, rheumatoid arthritis, and Alzheimer’s, reveals novel enzymatic functions and provides a foundation for future therapeutic approaches targeting these enzymes. Scientists at Scripps Research have developed atomic-level structural models of enzymes linked to autoimmune and inflammatory conditions, such as lupus and Alzheimer’s disease. When nucleic acids, such as DNA or RNA, accumulate in a cell’s cytoplasm, they trigger an alert to the immune system. Under normal circumstances, enzymes are tasked with clearing out these nucleic acids to prevent problems. However, if these enzymes fail to function properly and the immune system intervenes, it may result in autoimmune and inflammatory diseases. In a new study recently published in the journal Structure, Scripps Research scientists present the previously undescribed structure of two of these nucleic acid-degrading enzymes—PLD3 and PLD4. Understanding these enzymes’ structures and molecular details is an important step toward designing therapies for the various diseases that arise when they malfunction, which include lupus erythematosus, rheumatoid arthritis, and Alzheimer’s disease. “These enzymes are important for cleaning up the cellular environment, and they also set the threshold for what is considered an infection or not,” says senior author David Nemazee, PhD, professor in the Department of Immunology and Microbiology at Scripps Research. “I’m hoping someday we may be able to help patients based on this information.” Enzyme Functionality and Analysis Techniques Enzymes are proteins that speed up chemical reactions by binding and reacting to specific molecules called substrates. In the case of PLD3 and PLD4, the substrate is a strand of RNA or DNA, which the enzymes break down nucleotide by nucleotide. The team used X-ray crystallography to build atomic-scale models of the PLD3 and PLD4 in multiple states or situations, allowing them to examine how their shapes changed over the course of the catalytic reaction. This included when the enzymes were resting, or when they were actively bound to a substrate. “These models allow us to visualize PLD3 and PLD4 very clearly and with high resolution, so we know exactly how every atom interacts, meaning we can deduce how the enzymes work,” says first author Meng Yuan, a staff scientist in the Department of Integrative Structural and Computational Biology at Scripps Research. Structural models of PLD3 and PLD4, enzymes that degrade nucleic acids in the cytoplasm. The enzymes’ active (or binding) sites are indicated with black arrows. Credit: Scripps Research The structural analyses revealed that PLD3 and PLD4 are structurally similar and that they degrade DNA and RNA in a very similar fashion, even though PLD4 is a larger protein. Both enzymes degrade nucleic acids via a two-step process. “We call this process a two-step catalysis: bite down and release,” says Yuan. “In the first step, the enzyme bites down on the DNA strand and separates a single ‘brick’ or nucleotide from the rest of the strand, and in the second step, it opens its ‘mouth’ and releases the brick to be recycled.” Because the enzymatic reaction happens so quickly—within milliseconds—researchers needed to use an alternative substrate to visualize the enzymes’ structure during catalysis. To do this, they incubated the enzymes together with a molecule that looks very similar to the DNA that the enzyme usually degrades, but that the enzymes degrade much more slowly. Discovering New Enzymatic Functions This method uncovered a previously unknown function for one of the enzymes: In addition to biting off nucleotides from single-stranded RNA and DNA, PLD4 also showed phosphatase activity, which means it might also be involved in breaking down DNA’s phosphate backbone. “I think it’s amazing that the crystal structure told us about this phosphatase activity,” says Nemazee. “To discover new enzymatic activity is unheard of in structural biology. It’s only because Meng was able to solve such an amazingly accurate and detailed structure that he could inform us about this extra enzymatic activity that we had no idea about.” After they had elucidated PLD3 and PLD4’s usual structure, the researchers examined the structure of variants that are associated with diseases, including Alzheimer’s and spinocerebellar ataxia. These analyses revealed that some of these variants had decreased enzymatic capability, while others—including a mutation associated with late-onset Alzheimer’s—appeared to be more active. “Some of our data suggests that one of these Alzheimer’s-associated enzyme variants might function better, which was a surprise to me, but it also may be less stable and more easily aggregated,” says Nemazee. The researchers plan to continue investigating the structure and function of these enzymes. Their next steps include exploring possible ways of inhibiting the enzymes in scenarios where they are overactive, and they also plan to investigate the possibility of replacing the enzymes in people who carry non-functional (or non-working) versions. Reference: “Structural and mechanistic insights into disease-associated endolysosomal exonucleases PLD3 and PLD4” by Meng Yuan, Linghang Peng, Deli Huang, Amanda Gavin, Fangkun Luan, Jenny Tran, Ziqi Feng, Xueyong Zhu, Jeanne Matteson, Ian A. Wilson and David Nemazee, 26 March 2024, Structure. DOI: 10.1016/j.str.2024.02.019 This study was supported by the National Institutes of Health (grants R01AI142945 and RF1AG070775) and Skaggs Institute for Chemical Biology at Scripps Research.

DVDV1551RTWW78V